Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 10.

Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne, Hemmaway, Claire, Greaves, Paul, Clark, Richard, Copland, Mhairi and Russell, Nigel 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194 (2) , pp. 298-308. 10.1111/bjh.17501

Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan and Spearing, Ruth 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8) , pp. 890-901. 10.1200/JCO.20.01170

Greenwood, Rosemary, Pell, Julie, Foscarini-Craggs, Paula, Wale, Katharine, Thomas, Ian and Bradbury, Charlotte 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21 (1) , 873. 10.1186/s13063-020-04798-x

Burnett, Alan K., Hills, R K, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32 , pp. 2693-2714. 10.1038/s41375-018-0148-3

Freeman, Sylvie D., Hills, Robert K., Virgo, Paul, Khan, Naeem, Couzens, Steve, Dillon, Richard, Gilkes, Amanda, Upton, Laura, Nielsen, Ove Juul, Cavenagh, James D., Jones, Gail, Khwaja, Asim, Cahalin, Paul, Thomas, Ian, Grimwade, Davied, Burnett, Alan K. and Russell, Nigel H. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36 (14) , pp. 1486-1497. 10.1200/JCO.2017.76.3425

Knapper, Steven, Russell, Nigel, Gilkes, Amanda, Hills, Robert K., Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648

Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian and Clark, Richard 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101 (6) , pp. 724-731. 10.3324/haematol.2016.141937

Burnett, A. K., Russell, N. H., Hills, Robert Kerrin, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-F., Cahalin, P., Dennis, M., Friis, L., Thomas, Ian, Milligan, D. and Clark, R. E. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125 (25) , pp. 3878-3885. 10.1182/blood-2015-01-623447

Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170 (1) , pp. 80-84. 10.1111/bjh.13398

Dennis, M., Russell, N., Hills, Robert Kerrin, Hemmaway, C., Panoskaltsis, N., McMullin, M. F., Kjeldsen, L., Dignum, H., Thomas, Ian, Clark, R. E., Milligan, D. and Burnett, Alan 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125 (19) , pp. 2923-2932. 10.1182/blood-2014-10-608117

This list was generated on Sun Sep 19 04:44:11 2021 BST.